Keyword: CEPI

There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.

In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.

Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.

Profectus’ Lassa candidate is based on its VesiculoVax vaccine delivery platform, which uses vesicular stomatitis virus as vector.

Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.

With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.

The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.

The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.

The public-private vaccine coalition will support Themis' development of Lassa fever and MERS vaccines through phase 2.

Drugmakers have joined with governments and nonprofits around the world to launch an alliance that’ll take a proactive approach to potential deadly outbreaks.